New stem cell therapy shows 'promising' results for treating hair loss in preclinical trials
Print Close
By Angelica Stabile
Published June 25, 2025
Researchers at the San Carlos Clinical Hospital in Madrid may have targeted a potential solution for hair loss.
A recent study analyzed the effect of injecting mice's skin with stem cells from human fat — "adipose-derived stem cells (ASCs)" — as a means of treating androgenetic alopecia (AGA), more commonly known as male- or female-pattern hair loss.
The team found that male mice achieved the best hair regrowth after three weeks when they received low-dose ASCs, combined with an energy-boosting molecule called adenosine triphosphate (ATP).
HAIRSTYLISTS AND MEDICAL EXPERT CONFIRM TEMPORARY HAIR LOSS AFFECTING OZEMPIC USERS
Low-dose and high-dose ASC treatments along with ATP led to no hair regrowth improvement in females, but medium-dose ASC plus ATP led to greater regrowth.
The researchers concluded that hair regrowth was improved in "all experimental groups" where male mice received stem cell solutions supplemented with ATP.
The findings were published in the journal Stem Cell Research & Therapy.
Lead study author Dr. Eduardo López Bran — dermatologist and professor at The Complutense University of Madrid — shared his expectations for the study in an interview with Fox News Digital.
THIS DAILY BEAUTY ROUTINE COULD BE RUINING YOUR HAIR, EXPERTS WARN
"We expected good results, but not such a high level of success," he said. "We're talking about a very high degree of hair regrowth in both male and female mice."
With appropriate doses, the researchers achieved "very high percentages" of hair regrowth, noting that 100% of the male mice and up to 90% of the female mice regrew hair.
"These results demonstrate that advanced therapies may represent a new therapeutic approach for many diseases for which no effective treatments are currently available," Bran went on.
"Achieving such promising results in the preclinical phase with a completely novel approach to androgenetic alopecia — one that avoids chronic treatment and is also safe — is a significant scientific milestone."
"We're talking about a very high degree of hair regrowth in both male and female mice."
The main limitation of the study was the thinness of mouse skin, Bran noted, which "posed a challenge in administering the therapy."
CLICK HERE TO GET THE FOX NEWS APP
"This required the development of protocols to minimize experimental variability, and will be a key factor when studies in humans begin," he said.
These new findings should be "interpreted with caution and scientific rigor," Bran cautioned.
"Although the results in mice represent significant progress, it is also true that it is essential to wait for clinical benefits in humans to be confirmed."
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
The researcher encouraged those with androgenetic alopecia to continue consulting with their dermatologists and to follow prescribed treatments as research develops.
"It is important to remain hopeful. Research advances are pointing toward possible solutions that, in the future, may offer long-lasting results without the need for continuous treatment to maintain benefits," Bran added.
"This study is small, and more research is needed on this method as a potential treatment option."
Looking ahead to human clinical trials, researchers are "actively working" on confirming safety for men and women between 18 and 50 years old with moderate androgenetic alopecia, the researcher noted.
"If everything progresses as expected, the most optimistic timeline points to the treatment becoming available in approximately five years," he said.
In a separate interview with Fox News Digital, Dr. Brendan Camp, M.D., a New York-based dermatologist who was not involved in the study, commented on the potential for this method.
"While not commercially available, this study suggests that injection of stem cells supplemented with ATP into scalp skin could potentially encourage hair regrowth in individuals with androgenetic alopecia," he reiterated.
For more Health articles, visit www.foxnews.com/health.
"This study is small, and more research is needed on this method as a potential treatment option for androgenetic alopecia."
Until then, Camp encourages people to focus on currently available and "well-studied" treatments to address hair loss, and to visit a board-certified dermatologist for evaluation. Print Close
URL
https://www.foxnews.com/health/new-stem-cell-therapy-shows-remarkable-success-treating-hair-loss-preclinical-trials
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
27 minutes ago
- Medscape
Novel Drug Lowers Urate Levels but Gout Flares Persist
BARCELONA, Spain — The investigational oral compound SAP-001 had a significant and sustained urate-lowering effect in people with refractory gout, according to findings of a phase 2b study reported at the European Alliance of Associations for Rheumatology (EULAR) 2025 Annual Meeting. The proportion of people achieving a target serum urate level of < 6 mg/dL (360 µ mol/L) after 12 weeks was 10.5% for placebo and ranged from 43.8% to 70.0% for those given one of three different once-daily doses of SAP-001. A dose response was not seen in the main analysis, however; the proportions of people meeting this primary efficacy endpoint were 43.8% (n = 32) for a 60-mg dose but 56.3% (n = 16) and 70.0% (n = 20) for 10- and 30-mg doses, respectively. Kenneth Saag, MD This could have been because of issues with adherence, said the presenting author Kenneth Saag, MD, professor and director of the Division of Clinical Immunology and Rheumatology at The University of Alabama at Birmingham. Ad hoc analyses, which had not been preplanned, showed that 'some subjects had not been exposed to the drug post baseline,' Saag said. 'This seemed to strongly correlate with adherence to therapy, as indicated by [a patient's daily] dosing diary, pill counts, and post-study patient interviews.' When people with nonquantifiable serum urate levels were excluded from the analyses, there was more of a dose response, particularly if a lower urate level of < 5 mg/dL (300 µ mol/L) had been achieved. Notably, Saag reported that the urate-lowering effects were maintained until the end of treatment at 6 months, and a good proportion of participants also met the harder target of a serum urate level of < 5 mg/dL. First-in-Class 'SAP-001 is a drug that has a different renal urate transporter mechanism of action from other urate-lowering drugs that are currently available or are under development,' said Saag, a former president of the American College of Rheumatology. Although Saag did not present the specific mode of action for the drug, he noted, 'it appears to predominantly be targeting GLUT [glucose transporter] 9, which is located on the basal lateral aspect of the renal tubule.' This differs from most other uricosuric therapies, which targeted renal transporters on 'the apical side of the tubule, such as OAT [organic anion transporters] and URAT [urate transporter]-1,' he added. 'So this drug has the potential as a novel therapeutic option in gout,' Saag said. Study Design and Patient Population The study was a 6-month randomized, double-blinded, placebo-controlled investigation of three different doses of SAP-001 for the management of refractory gout. A total of 403 adults with refractory gout between 18 years and 75 years of age who were living in the US were screened for eligibility, with 87 finally randomized. For inclusion, participants had to either have not responded to at least 4 weeks of standard of care treatment with a xanthine oxidase inhibitor prior to study entry or have a contraindication to its use. They also had to have serum urate levels of ≥ 7 mg/dL at both the screening and randomization visit. A 1:1:1:2 ratio was used to randomly allocate participants to the four treatment groups: placebo or SAP-001 10 mg, 30 mg, or 60 mg. Baseline characteristics were reasonably similar among the four groups. The mean ages in each group were 55.9 years, 54.2 years, 50.3 years, and 52.5 years, respectively. The majority were men (89.5%, 87.5%, 90.0%, and 96.9%, respectively), and most identified themselves as White and Hispanic individuals. The mean BMI was around 32, and baseline serum urate levels were about 8.37 mg/dL (~500 µ mol/L). The average duration of gout since diagnosis was about 10 years, and 1 in 5 had palpable tophi. Safety Findings Saag and associates reported in their abstract that SAP-001 was well tolerated overall. There were no treatment-emergent serious adverse events in the SAP-001 patients, and all adverse events were of a mild to moderate intensity. The most frequently reported adverse events were gout flares; these occurred in 26.3% of placebo-treated individuals and in 25%, 30%, and 25% of participants treated with SAP-001 10 mg, 30 mg, and 60 mg, respectively. The majority of these gout flares occurred within the first few months of the study, although some people taking SAP-001 experienced gout flares up to 4-6 months later. The longest duration of gout flares in the SAP-001 groups was 11.5 days in the 60-mg SAP-001 group, and the shortest was 6.2 days in the 30-mg group. The mean durations of gout flares in the 10-mg and placebo groups were 6.5 and 7.4 days, respectively. The time to the first gout flare was shortest in the 30-mg SAP-001 group, at 21.2 days, followed by 40.5 days in the 60-mg group, 50.3 days in the 10-mg group, and 66.4 days in the placebo group. As for adverse events of special interest, one participant who had taken the 30-mg dose of SAP-001 developed a hepatobiliary disorder, and another who had taken this dose had raised aspartate aminotransferase, an outcome that also occurred in one patient each in the 10- and 60-mg dosing groups. Increased blood creatinine levels were seen in two participants in the 10-mg group and three in the 60-mg group. Hepatic enzymes were elevated in one patient in the placebo group and one patient in the 30-mg group. One patient in the 60-mg group had acute kidney injury. Limitations and Conclusion Saag acknowledged that this was an early-phase study, and its small sample size meant the effect on flares and tophi was limited. However, he concluded that SAP-001 may be a 'novel, efficacious, and generally safe oral urate-lowering treatment option for difficult-to-treat gout populations, and it merits further investigation with a focus on treatment adherence.' Helga Lechner-Radner, Wien, Austria, who co-chaired the late-breaking abstract session during which Saag had presented these data, questioned whether people with genetic conditions that could cause hyperuricemia had been included or excluded from the study. Saag responded: 'That wasn't specifically a form of [inclusion]/exclusion in this study; in future studies, that would certainly be reasonable to look at.' This study was funded by Shanton Pharma. Saag reported acting as a consultant to Shanton Pharma as well as Amgen, Arthrosi, ATOM, Crystalys, LG, and Sobi. He also reported being an investigator for Arthrosi, Crystalys, Inventis, and LG. Several coauthors on the abstract were employees of Shanton Pharma.
Yahoo
2 hours ago
- Yahoo
GenSight Biologics Announces Significant Milestone in New Manufacturing Partnership with Catalent
Upstream phase of LUMEVOQ® manufacturing process successfully transferred Milestone follows successful manufacture of drug product batch to be used for named early access program (AAC) and dose-ranging study in France Partnership expected to improve yield and upgrade analytical methods ahead of clinical use and regulatory submissions PARIS, June 26, 2025--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the successful transfer of the upstream phase of the manufacturing process for LUMEVOQ®, the Company's gene therapy candidate product for the rare mitochondrial disease Leber Hereditary Optic Neuropathy (LHON), to its new manufacturing partner, Catalent, Inc. "This outstanding result is a significant milestone in GenSight's strategy for securing the supply of LUMEVOQ for clinical use and for supporting the planned regulatory submissions," commented Scott Jeffers, Chief Technical Officer of GenSight Biologics. "Our new partnership is proving to be highly effective, not just in completing the tech transfer process successfully, but also in improving the yield and upgrading the analytical methods used to reinforce control over the safety and quality of each batch. The level of collaboration and coordination between our teams has been truly impressive." Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) whose mission is to develop, manufacture, and supply products that help people live better and healthier lives. It is the only CDMO with a successfully commercialized gene therapy produced in their facility. Catalent offers gene therapy companies both production and in-house testing capabilities, and the GMP capacity at the facility used for LUMEVOQ® will provide GenSight Biologics greater flexibility in the manufacture of the gene therapy. Catalent successfully manufactured the drug product batch that was released as safe for human use in November 2024 and which will be the source of product supply for the named patient early access program (AAC) and dose-ranging study in France. After the tech transfer is completed, Catalent will also manufacture the drug for the planned global Phase III trial RECOVER and the regulatory submissions. The Partnership as a Critical Element of GenSight Biologics' Strategy Following agreement with the French agency ANSM to consider opening the AAC program expeditiously after approval of a dose-ranging study, the Company is currently implementing a financing strategy, as it continues to advance its global marketing authorization strategy: Preparation for regulatory consultations in the US and EU Planning for the global Phase III trial scheduled to begin in 2026, designed to meet FDA and EMA requirements Completing the transition to a new manufacturing partner (Catalent) to secure reliable clinical and commercial supply Advancing preparations for MHRA submission in the United Kingdom "Our partnership with a manufacturing powerhouse like Catalent is a critical enabler of our global strategy," explained Laurence Rodriguez, CEO of GenSight Biologics. "The outputs from their work with our team will allow us to reassure regulators that we have surmounted the challenges we faced in the past and, ultimately, to fulfill our mission to provide LHON patients a safe and effective treatment for their urgent unmet need." About GenSight Biologics GenSight Biologics S.A. is a clinical-stage biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. GenSight Biologics' pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. GenSight Biologics' lead product candidate, GS010 (lenadogene nolparvovec) is in Phase III in Leber Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease that leads to irreversible blindness in teens and young adults. Using its gene therapy-based approach, GenSight Biologics' product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery. About Leber Hereditary Optic Neuropathy (LHON) Leber Hereditary Optic Neuropathy (LHON) is a rare maternally inherited mitochondrial genetic disease, characterized by the degeneration of retinal ganglion cells that results in brutal and irreversible vision loss that can lead to legal blindness, and mainly affects adolescents and young adults. LHON is associated with painless, sudden loss of central vision in the 1st eye, with the 2nd eye sequentially impaired. It is a symmetric disease with poor functional visual recovery. 97% of subjects have bilateral involvement at less than one year of onset of vision loss, and in 25% of cases, vision loss occurs in both eyes simultaneously. About LUMEVOQ® (GS010; lenadogene nolparvovec) LUMEVOQ® (GS010; lenadogene nolparvovec) targets Leber Hereditary Optic Neuropathy (LHON) by leveraging a mitochondrial targeting sequence (MTS) proprietary technology platform, arising from research conducted at the Institut de la Vision in Paris, which, when associated with the gene of interest, allows the platform to specifically address defects inside the mitochondria using an AAV vector (Adeno-Associated Virus). The gene of interest is transferred into the cell to be expressed and produces the functional protein, which will then be shuttled to the mitochondria through specific nucleotidic sequences in order to restore the missing or deficient mitochondrial function. "LUMEVOQ" was accepted as the invented name for GS010 (lenadogene nolparvovec) by the European Medicines Agency (EMA) in October 2018. LUMEVOQ® (GS010; lenadogene nolparvovec) has not been registered in any country at this stage. View source version on Contacts GenSight Biologics Chief Financial OfficerJan Eryk Umiastowskijeumiastowski@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
Womb lining test offers miscarriage hope to women
UK scientists say they have developed a test which can help identify women with an abnormal womb lining that increases their risk of miscarriage. They say their work could pave the way for new treatments for those going through repeated pregnancy loss. In some women with a history of miscarriage, the womb lining doesn't react the way it should - transforming into a supportive place for the embryo to implant, the Warwick University team discovered. Charities say the findings could help provide an explanation, in some cases, for the trauma and devastation of recurrent miscarriage. Around one in six of all pregnancies are lost, most before twelve weeks, and each miscarriage increases the risk of another one happening. To date, most research in this area has focused on the quality of the embryo, with much less known about the role of the womb lining. Dr Jo Muter, study author and researcher at Warwick Medical School, said: "Many women are told they've just had 'bad luck', but our findings show that the womb itself may be setting the stage for pregnancy loss, even before conception takes place." The job of the womb lining is to receive the embryo and help it develop during pregnancy, thanks to a reaction which converts cells into a different, supportive state. But when that reaction is messed up and doesn't fully happen, the risk of bleeding and early pregnancy rises. Once a woman has had one faulty reaction, she is more likely to have another, the researchers say. They've developed a new test which can measure signs of a healthy or defective reaction in the womb lining, which is being piloted to help more than 1,000 patients at Tommy's National Centre for Miscarriage Research at University Hospital Coventry & Warwickshire (UHCW). Charlie Beattie, 37, had countless early miscarriages over the course of four years, to the point where "a positive pregnancy test wasn't exciting any more", she says. She and her husband Sam, from Leamington Spa, felt devastated and resigned to considering other options for having a family. Then they found out about at a trial taking place at the miscarriage research centre. Charlie had a sample of her womb taken, and the new test showed it was not "hospitable for babies", she says. After taking the drug sitagliptin for three months, she had a pregnancy which finally stuck - and nine-week-old June is the joyful result. "She's a tiny miracle. It doesn't feel real," says Charlie. She admits being anxious all the way through her pregnancy until June was safely in her arms. Even the pregnancy scans were a new experience. "We'd never seen anything on a scan before that moved," she says. "When they said 'I can see it, it's in the right place', we both burst into tears." Anyone can refer themselves to the clinic, but it has a long waiting list and funding issues mean patients must contribute to the cost of the test. Dr Jyotsna Vohra, director of research at Tommy's, said care and treatment for those who experience pregnancy or baby loss varied unacceptably across the UK. "There should be no barriers to accessing any test or treatment that has been proven to make a difference. "We hope NHS decision-makers will look carefully at the results of the Coventry pilot project and consider rolling this test out nationwide, so that everyone who might benefit has that opportunity." Dr Muter says the next step is to use the test to assess potential drug treatments. Sitagliptin, usually used to treat diabetes, is the go-to option for womb lining issues but there may be other existing drugs which can be repurposed, she added. With 80% of drugs not tested on pregnant women, it's unclear which ones might be effective.
